SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to recent policy moves aimed at driving down mortgage rates, which has ignited strong community optimism for a revitalized housing market. Investors are actively discussing the potential for increased transaction volume and a significant price appreciation, with many anticipating a move towards double-digit levels for the company's stock.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid buzz over its strategic agreement with Meta Platforms to power AI data centers and a U.S. Department of Energy deal for a radioisotope pilot facility. The community is intensely discussing whether the company's long-term potential in advanced nuclear energy, bolstered by government initiatives and AI's immense power needs, outweighs its current lack of commercial revenue. Anticipation builds around an upcoming congressional hearing on nuclear energy dominance, which investors believe could further accelerate its market position.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is generating significant buzz as its pivotal PDUFA date for Anaphylm rapidly approaches, with many anticipating a potential game-changing approval for the device-free epinephrine film. Community discussion highlights Anaphylm's unique convenience and the FDA waiving an Advisory Committee meeting as strong positive signals, while a substantial short interest fuels speculation of an impending squeeze. Conversely, some investors remain cautious, weighing past regulatory challenges against the promise of a novel, needle-free allergy treatment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is experiencing significant volatility and a steep downtrend, largely driven by persistent warmer-than-expected winter forecasts that continue to suppress heating demand. The community is actively debating whether natural gas prices have bottomed, with many expressing frustration over BOIL's leveraged decay while others eagerly anticipate a potential "polar vortex" or colder weather to trigger a market rebound.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending amidst heightened discussions regarding the critical role of Small Modular Reactors in meeting the escalating energy demands from AI data centers and broader market needs. The community is actively debating the company's long-term potential as the sole NRC-approved SMR provider, with bulls pointing to anticipated government support and contracts, while others express caution regarding its pre-revenue state and historical volatility. This positions NuScale Power within a broader conversation about the future of energy infrastructure for next-generation technology.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is actively trending as it solidifies strategic nuclear energy partnerships with companies like Vistra and Oklo, a move critically observed by the community as indispensable for powering its ambitious AI data center expansion. This development highlights the escalating energy demands of the AI race, prompting discussions among investors about Meta's long-term vision and its ability to execute. Additionally, China's review of Meta's Manus AI acquisition is generating buzz, adding a layer of geopolitical interest to the company's recent activities.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is trending following overwhelmingly positive feedback from its FDA Type B meeting, confirming a clear path for its sonelokimab (SLK) Biologics License Application (BLA) in hidradenitis suppurativa without additional clinical trials. This significant de-risking event has ignited strong optimism among investors, who anticipate substantial analyst upgrades and a renewed focus on potential acquisition by larger pharmaceutical companies, particularly given SLK's strong position in the immunology market. Community discussions highlight the belief that the stock is fundamentally undervalued, expecting a significant re-rating as regulatory clarity and strategic appeal of the asset drive conversation.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending following the completed Renergen acquisition, which integrates helium and LNG production, and an 'Overweight' analyst rating from Cantor Fitzgerald. The community views these developments as key steps differentiating ASPI in the high-growth nuclear and materials sector, particularly for its potential in HALEU for advanced reactors and silicon-28 for AI computing. Discussions highlight the company's strategic positioning within the broader 'atomic renaissance' amidst anticipation of future revenue streams.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, Sunset, and Asset Closure. The Retail segment sells electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Sunset segment includes generation plants with announced retirement plans. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp (VST) is trending as it aggressively expands its power generation capacity, notably with a $4 billion acquisition of Cogentrix Energy's natural gas fleet, directly addressing the surging electricity demand from AI data centers. This strategic move, complementing earlier nuclear power contracts, positions Vistra as a pivotal supplier for hyperscalers, with the community actively debating its role in solving the critical 'AI energy bottleneck' amid recent market volatility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a trending topic amidst its active participation at CES 2026, where it is showcasing advancements in agentic voice and visual AI for vehicles and smart devices, alongside new partnerships with TomTom and Richtech Robotics. The community is buzzing with both optimism for significant growth and a potential short squeeze, given its high short interest, while some express frustration over perceived price suppression despite positive developments. This highlights a broader market focus on the real-world deployment of conversational and agentic AI across various industries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics (IMTX) delivered earnings and revenue surprises of -73.68% and -62.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

Dare Bioscience Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$2.07
Prev Close	$1.97
Open	$1.99
Dividend Yield	0.00%
50-Day Moving Average	$1.94
Beta	0.53
Avg. Volume	298,233.36
PE Ratio	-4.69

52-Week High	$9.19
52-Week Low	$1.61
Market Capitalization	$28.15M
EPS (Annual)	-$0.477
Price to Book	10.09
Revenue Per Employee	$425.39
Enterprise Value/EBITDA	N/A

DARE
Dare Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DARE News

DAREDare Bioscience Inc